MANE

MANE (Veradermics, Incorporated) Analyst Note Date: 2026-06-20 Current Price: $93.87

1. Structural Readiness

State: Forming Current Price: $93.87 Extension: N/A (Price is within the consolidation range, not extended above the breakout). ATR Current: 7.3% (Very High).

Coil Classification: FORMING.

2. Thesis Layer

Thesis Classification: TACTICAL / Setup-Led. There is no named secular macro thesis attached to this name as of 2026-06-20. The investment case is not driven by a broad market rotation or a specific macroeconomic theme (e.g., "AI Infrastructure" or "Energy Transition"). Instead, the conviction must be derived entirely from the quality of the technical setup (the forming coil) and the binary nature of the business fundamentals (clinical trial outcomes). The name is judged strictly on its structural readiness and the specific catalysts provided by the company's clinical pipeline.

3. Business Overview

Company: Veradermics, Incorporated (MANE) Industry: Biotechnology / Dermatology Business Model: Clinical-stage biopharmaceutical company focused on the development of novel treatments for Pattern Hair Loss (PHL). The company operates on a "high-risk, high-reward" model typical of late-stage biotech, relying on the successful completion of Phase 3 trials to secure regulatory approval and subsequent commercialization.

Key Business Fundamentals (as of 2026-06-20):

• Pipeline Status: The company is advancing its lead asset, VDPHL01, through a registration-directed Phase 3 program. As of the March 30, 2026 filing, the program consists of three clinical trials: two in male patients and one in female patients.
• Clinical Progress:
• Male Cohort: Enrollment in the confirmatory registration-directed Phase 3 trial in male patients with mild-to-moderate PHL was completed as of May 12, 2026. Preliminary data from the male cohort (4-month treatment) was announced in October 2025, showing an average increase in non-vellus TAHC of 30.3 hairs/cm² (QD) and 33.0 hairs/cm² (BID).
• Female Cohort: Enrollment in the female Phase 2/3 trial was ongoing as of March 30, 2026, with the female cohort initiating enrollment later than the male cohort.
• Safety Profile: As of the May 12, 2026 filing, no treatment-related Serious Adverse Events (SAEs) and no Adverse Events of Special Interest (AESIs) of cardiac origin were observed in the study.
• Market Opportunity: Management estimates the current U.S. commercial opportunity for PHL treatments for men and women is valued at approximately $9 billion annually. The company notes that current treatment options are limited, plagued by high failure rates, and associated with patient dissatisfaction.
• Commercialization Strategy: Management expects to release 12-month data from the Phase 3 study and additional Phase 2 data in 2026. The initial marketing application could seek approval in male patients first, followed by an sNDA for females, or pursue simultaneous approval depending on trial completion timing.
• Physician Sentiment: A study cited in the May 12 filing indicated that 73% of Healthcare Providers (HCPs) would be "very or extremely likely" to prescribe VDPHL01 once approved, with an expectation to treat 52% of their male PHL patients with the drug.

4. Archetype and Conviction Stack

Archetype: Growth Leader / Clinical Catalyst. This name fits the archetype of a late-stage biotech "Growth Leader" in the context of a specific therapeutic area, driven by binary clinical data rather than current revenue or earnings. It is not a deep value recovery (no prior earnings to recover from), nor a cyclical recovery. It is a pure play on the successful execution of a clinical trial.

Conviction Stack Analysis:

• Thesis Strength: Moderate. The thesis is binary (approval vs. failure) and lacks a secular macro tailwind, making it purely tactical.
• Evidence Quality: High. The evidence base (E1–E15) is robust for a clinical-stage company, citing specific enrollment completion, statistical significance (p<0.0001), safety data, and HCP sentiment.
• Rerating Potential: High. If the 12-month data release (expected in 2026) confirms the preliminary efficacy and safety profile, the stock could re-rate significantly based on the $9B TAM and high HCP interest.

5. Invalidations, Strengtheners, and Gaps

What Would Invalidate the Case:

• Fundamental: Negative topline data from the Phase 3 male trial (e.g., failure to meet primary endpoints) or the emergence of safety signals (cardiac AESIs) not seen in the preliminary data.
• Regulatory: FDA feedback indicating the current trial design is insufficient for approval.

What Would Strengthen the Case:

• Technical: A confirmed daily close above the coil's resistance (breakout level), accompanied by volume.
• Fundamental: Positive topline data release from the Phase 3 male trial (expected in the second half of 2026) confirming the preliminary efficacy and safety.
• Strategic: Announcement of a partnership or licensing deal to commercialize the asset, reducing execution risk.

Gaps in the Evidence Base:

• Financials: No specific cash runway, burn rate, or liquidity data is provided in the evidence block. The ability to fund the trial to completion and commercialization is a critical unknown.
• Female Data: While the male data is advanced, the female trial data is still pending, and the timeline for female topline data is "determined as the trial progresses," creating uncertainty on the full market addressability timeline.
• Commercialization Costs: No data on the projected cost of commercialization or the specific timeline for NDA submission beyond the general "2026" window.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Enrollment in Phase 3 male trial completed; Preliminary data shows statistically significant hair growth (p<0.0001) with no cardiac safety signals; HCP sentiment indicates 73% likelihood to prescribe. Key risks: Binary clinical trial outcome risk; Very high ATR (7.3%) indicates elevated volatility and potential for sharp downside if structure breaks; Lack of disclosed cash runway or liquidity data. Sizing hint: Position size should be reduced relative to a confirmed breakout setup due to the "Forming" status and high volatility; treat as a satellite holding. Expected path: Price likely to remain in consolidation until the 12-month data release in late 2026; a breakout would require positive data confirmation. Expected horizon: 6 to 12 months (aligned with the expected data release window).